Cyberonics Stumbles and ANS Lends a Hand
An unexpected and unfavorable ruling from the FDA has left Cyberonics officials angry and frustrated and has put in jeopardy the depression opportunity the company was counting on. Also on Cyberonics' plate: an unwelcome merger bid from rival neurostimulation company, ANS.
You may also be interested in...
The seeds planted in neurostimulation ventures over the past 10 years have produced more disappointments than results, but the fallow period is over. The Food & Drug Administration recently cleared Neuronetics to begin selling its NeuroStar TMS as a treatment for people who haven't responded to a drug regimen taken during their current episode of depression. This is good news for scores of venture-backed neurostimulation companies, although Neuronetics is somewhat unique. It is developing a non-invasive device that delivers magnetic, rather than electrical pulses.
Medtronic is the acknowledged leader in one of the hottest device sectors-neurostimulation-but even this giant struggles with problems of limited market penetration. So Medtronic is bringing a new approach to this area: an aggressive clinical trials strategy to differentiate its products and drive physician adoption. Who better to run the business than a clinical trials expert? Richard Kuntz talks about future neuro opportunities and the current challenges facing device clinical trials.
The rise of interest in neurostimulation and neuromodulation approaches is leading venture capitalists and large medical device companies to develop devices to prevent or block seizures. The devices would be used primarily on patients who don't respond to drugs for epilepsy.